Published research demonstrates high specificity of Alzinova's ALZ-201 antibody which may contribute to good efficacy and favourable side-effect profile
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Alzinova AB (publ) ("Alzinova" or the "Company") announces today that a new scientific article has been published in the prestigious journal Alzheimer's Research & Therapy presenting preclinical results demonstrating that the ALZ-201 antibody has specificity for the toxic oligomers believed to be the cause of Alzheimer's disease. Furthermore, the research shows that ALZ-201 has the potential to be "best-in-class" in the clinic with good efficacy and more favourable side-effect profile compared to other candidates.
The article presents new preclinical data on Alzinova’s antibody ALZ-201 demonstrating its unique specificity for a very toxic form of the peptide amyloid-β1-42 (Aβ42). This toxic Aβ42 is in an oligomeric form, which are different from the Aβ42 that aggregates into the plaques in the brain of patients. Oligomers are considered to be the form of Aβ that drives the disease. Given the antibody’s unique binding profile, it has the potential to become clinical best-in-class with good efficacy and a favourable side-effect profile. The monoclonal antibody ALZ-201 was developed and validated using the clinical vaccine candidate ALZ-101.
The paper describes how a multidisciplinary approach was used to develop ALZ-201 as a new unique monoclonal antibody that specifically binds to artificial Aβ42 oligomers but not to other forms of the same peptide. This was also validated on human material, where ALZ-201 had a strong neutralizing effect on toxic Aβ but did not bind to plaques. Taken together, the results indicate that it is a small amount of Aβ42 oligomers that account for the main toxic effect in AD, and that specificity for this form is likely to be necessary to obtain a good therapeutic effect of an antibody treatment.
The research presented in the paper also shows that ALZ-201 is completely different from other Aβ monoclonal antibodies, including aducanumab, lecanemab, and gantenerumab, in that unlike these, it binds specifically to toxic oligomers.
Alzinova is currently developing a humanized version of ALZ-201 for phase 1 clinical trials in patients with Alzheimer's disease. The Company's research shows that both ALZ-201 and the ALZ-101 vaccine have best-in-class potential, and clinical results from other players in the field reinforce the Company's strategy.
Chief Scientific Officer Anders Sandberg comments:
“We are very pleased to present our research results in the well-renowned scientific journal Alzheimer's Research & Therapy. The research described in the article clearly shows that a particular type of Aβ42 oligomer appears to be significantly more toxic than other forms of the same peptide, and we present a unique monoclonal antibody that can specifically neutralize it. We also show that this specificity is lacking in other antibodies in clinical development. These results strongly warrant continued development of ALZ-201 as a potential drug for Alzheimer's disease.”